Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
AstraZeneca
Express Scripts
McKinsey

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,921,348

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,921,348 protect, and when does it expire?

Patent 8,921,348 protects KORLYM and is included in one NDA.

Summary for Patent: 8,921,348
Title:Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.
Inventor(s): Belanoff; Joseph K. (Woodside, CA)
Assignee: Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:14/065,792
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,921,348
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 8,921,348

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 RX Yes Yes   Start Trial   Start Trial TREATING CUSHING'S SYNDROME   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.